MHMahsa Hojabri

Mahsa Hojabri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahsa Hojabri has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preliminary Development and Assessment of a Multiplex Assay for Human Papillomavirus Antibody Detection Using Commercial L1 Proteins

    by Arash Aslanabadi, Maryam Karimi, Laura Powell, Lisa Schumaker, Ashley Shutt, Mahsa Hojabri, Rahim Abbasi, Søren M. Bentzen, Kevin J. Cullen, Trevor A. Crowell, et al.

    Background: Human papillomavirus (HPV)‐associated cancers are preventable with vaccination. Serologic assays monitor antibody responses, but their complexity and cost pose limitations when evaluating population level immunity. We developed an L1‐based assay for the detection of multiple type‐specific HPV antibodies. Methods: The Luminex‐based assay used recombinant L1 proteins from seven HPVs (HPV‐6/11/16/18/35/45/58) for the detection of type‐specific immunoglobulin (Ig)G and IgA. Cutoffs were established using plasma from infants and children. The assay was optimized and qualified using a sample set from a blinded proficiency panel developed at the Frederick National Laboratory for Cancer Research. Results: Sensitivity and specificity for anti‐HPV‐6/11/16/18/58 IgG were 100% at the Mean + 3 standard deviation [SD] and Mean + 5 SD thresholds. Sensitivity for HPV‐45 was 100% and 92.9% at the +3 SD and +5 SD thresholds, respectively. IgA detection showed moderate positivity among vaccinated individuals, with peak estimates of 96.4% (HPV‐11) and 85.7% (HPV‐58) at the +3 SD threshold. IgA was correlated with IgG (Spearman's ρ = 0.74). The L1‐assay differentiated high, intermediate, low, and negative response groups from the blinded samples for all HPV genotypes ( p < 0.0001). Conclusion: The L1‐binding assay has the potential to be a scalable option for high‐throughput detection of broad‐spectrum HPV immunoglobulins, but further standardization and validation are needed.

  • Open Access

    Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo

    by Maryam Karimi, Arash Aslanabadi, Ben Atkinson, Mahsa Hojabri, Arshi Munawwar, Roza Zareidoodeji, Krishanu Ray, Parham Habibzadeh, Hanife Nur Karakoc Parlayan, Anthony DeVico, et al.


  • Open Access

    A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

    by Mohammad M. Sajadi, Abdolrahim Abbasi, Zahra Rikhtegaran Tehrani, Christine Siska, Rutilio Clark, Woo Chi, Michael S. Seaman, Dieter Mielke, Kshitij Wagh, Qingbo Liu, et al.

    Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with “first generation” bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of “enhanced” antibodies will be required for optimal clinical utility, while preserving or enhancing cGMP manufacturing capability. Here we report the engineering of an anti-CD4 binding-site (CD4bs) bnAb, N49P9.3, purified from the plasma of an HIV elite-neutralizer. Through a series of rational modifications we produced a variant that demonstrates: enhanced potency; superior antiviral activity in combination with other bnAbs; low polyreactivity; and longer circulating half-life. Additional engineering for manufacturing produced a final variant, eN49P9, with properties conducive to cGMP production. Overall, these efforts demonstrate the feasibility of developing enhanced anti-CD4bs bnAbs with greatly improved antiviral properties as well as potential translational value.

  • Open Access

    Comparative analysis of COVID-19 pneumonia in pregnant versus matched non-pregnant women: radiologic, laboratory, and clinical perspectives

    by Masoomeh Raoufi, Mahsa Hojabri, Danial Samiei Nasr, Hanieh Najafiarab, Aryan Salahi-Niri, Nastaran Ebrahimi, Shideh Ariana, Hamidreza Khodabandeh, Sara Salarian, Mehdi Azizmohammad Looha, et al.

    This study aimed to assess the severity and outcomes of COVID-19 in pregnant women, focusing on laboratory and radiological discrepancies between pregnant women and matched nonpregnant women. In this retrospective cross-sectional analysis, we matched 107 nonpregnant women with 66 pregnant women in terms of age, comorbidities, and the interval between symptom onset and hospital admission. Demographic, clinical, laboratory, and radiological data were collected, and chest CT scans were evaluated using a severity scale ranging from 0 to 5. Logistic regression and adjusted Cox regression models were used to assess the impact of various factors on pregnancy status and mortality rates. Differences in several laboratory parameters, including the neutrophil-to-lymphocyte ratio, liver aminotransferases, alkaline phosphatase, urea, triglycerides, cholesterol, HbA1c, ferritin, coagulation profiles, and blood gases, were detected. Radiologic exams revealed that nonpregnant women had sharper opacities, whereas pregnant women presented with hazy opacities and signs of crypt-organizing pneumonia. A notable difference was also observed in the pulmonary artery diameter. The mortality rate among pregnant women was 4.62%, which was comparable to the 5.61% reported in nonpregnant patients. Compared with nonpregnant patients, pregnancy did not significantly affect the severity or mortality of COVID-19. Our study revealed discernible differences in specific laboratory and imaging markers between pregnant and nonpregnant COVID-19 patients.


  • Open Access

    Sensorineural Hearing Loss and Hypothyroidism in A Patient with Cernunnos Deficiency; A Case Report

    by Yeganeh Farsi, Mahsa Hojabri, Golnaz Eslamian, Bibi Shahin Shamsian, Roxana Mansour Ghanaie, Mohammad Keramatipour, Zahra Chavoshzadeh, Shabnam Eskandarzadeh

    Cernunnos deficiency is a rare radiosensitive form of severe combined immunodeficiency (SCID). Herein, we report a patient with recurrent infections, birdlike face, microcephaly, Failure to thrive (FTT), and hypogammaglobinemia accompanied by considerable and rare features of sensorineural hearing loss and hypothyroidism with a mutation in splicing site of the third intron of non-homologous end joining 1 (NHEJ1) gene. The mutation was associated with T-B-NK + in flowcytometry. Distinct clinical manifestation along with a rarely reported genetic site mutation was noticeable in the reported case. The clinicians should be sensitive enough to suspect SCID in any patient with recurrent infections, microcephaly, FTT, and hypogammaglobinemia. Also, it is highlightable that every case of SCID with microcephaly should prompt us to the SCIDs with genetic mutations sensitive to radiation and further investigations are mandatory in highly suspicious patients.